A coding polymorphism of the kallikrein 1 gene is associated with essential hypertension: A tagging SNP-based association study in a Chinese Han population

Journal of Hypertension

Volumn 25, Issue 9, 2007, Pages 1821-1827

  Zhao, Weiyan ^a,b   Wang, Laiyuan ^a   Lu, Xiangfeng ^a   Yang, Wei ^a   Huang, Jianfeng ^a   Chen, Shufeng ^a   Gu, Dongfeng ^a,b  

^a FUWAI HOSPITAL   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

Author keywords

Case control study; Essential hypertension; Genetic; Kallikrein 1; Polymorphism

Indexed keywords

KALLIKREIN; KALLIKREIN 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE CONTROL STUDY; CHINESE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA DETERMINATION; ESSENTIAL HYPERTENSION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC CODE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; PRIORITY JOURNAL; SAMPLE; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TISSUE DISTRIBUTION;

EID: 34548427880     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328244e119     Document Type: Article

References (40)

1. Mullins LJ, Bailey MA, Mullins JJ. Hypertension, kidney, and transgenics: a fresh perspective. Physiol Rev 2006; 86:709-746.
2. Schmaier AH. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J Clin Invest 2002; 109:1007-1009.
3. Busse R, Fleming I. Molecular responses of endothelial tissue to kinins. Diabetes 1996; 45 (Suppl 1):S8-S13.
4. Mahabeer R, Bhoola KD. Kallikrein and kinin receptor genes. Pharmacol Ther 2000; 88:77-89.
5. Biyashev D, Tan F, Chen Z, Zhang K, Deddish PA, Erdos EG, Hecquet C. Kallikrein activates bradykinin B2 receptors in absence of kininogen. Am J Physiol Heart Circ Physiol 2006; 290:H1244-H1250.
6. Zinner SH, Margolius HS, Rosner B, Kass EH. Stability of blood pressure rank and urinary kallikrein concentration in childhood: an eight-year follow-up. Circulation 1978; 58:908-915.
7. Overlack A, Stumpe KO, Kolloch R, Ressel C, Krueck F. Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study. Hypertension 1981; 3:I18-I21.
8. Iwai N, Yasui N, Naraba H, Tago N, Yamawaki H, Sumiya H. Klk1 as one of the genes contributing to hypertension in Dahl salt-sensitive rat. Hypertension 2005; 45:947-953.
9. Zhao C, Wang P, Xiao X, Chao J, Chao L, Wang DW, Zeldin DC. Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats. Hypertension 2003; 42:1026-1033.
10. Zhang JJ, Wang C, Lin KF, Chao L, Chao J. Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats. Clin Exp Hypertens 1999; 21:1145-1160.
11. Yayama K, Wang C, Chao L, Chao J. Kallikrein gene delivery attenuates hypertension and cardiac hypertrophy and enhances renal function in Goldblatt hypertensive rats. Hypertension 1998; 31:1104-1110.
12. Evans BA, Yun ZX, Close JA, Tregear GW, Kitamura N, Nakanishi S, et al. Structure and chromosomal localization of the human renal kallikrein gene. Biochemistry 1988; 27:3124-3129.
13. Berge KE, Berg K. A TaqI RFLP at the human renal kallikrein (KLK1) locus. Clin Genet 1991; 40:256.
14. Slim R, Torremocha F, Moreau T, Pizard A, Hunt SC, Vuagnat A, et al. Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J Am Soc Nephrol 2002; 13:968-976.
15. Song Q, Chao J, Chao L. DNA polymorphisms in the 5′-flanking region of the human tissue kallikrein gene. Hum Genet 1997; 99:727-734.
16. Yu H, Song Q, Freedman BI, Chao J, Chao L, Rich SS, Bowden DW. Association of the tissue kallikrein gene promoter with ESRD and hypertension. Kidney Int 2002; 61:1030-1039.
17. Hua H, Zhou S, Liu Y, Wang Z, Wan C, Li H, et al. Relationship between the regulatory region polymorphism of human tissue kallikrein gene and essential hypertension. J Hum Hypertens 2005; 19:715-721.
18. Rossi GP, Taddei S, Ghiadoni L, Virdis A, Zavattiero S, Favilla S, et al. Tissue kallikrein gene polymorphisms induce no change in endothelium-dependent or independent vasodilation in hypertensive and normotensive subjects. J Hypertens 2006; 24:1955-1963.
19. De Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005; 37:1217-1223.
20. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova G, et al. Haplotype tagging for the identification of common disease genes. Nat Genet 2001; 29:233-237.
21. Consortium TIH. The International HapMap Project. Nature 2003; 426:789-796.
22. Gu D, Reynolds K, Wu X, Chen J, Duan X, Muntner P, et al. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension 2002; 40:920-927.
23. Gu D, Ge D, He J, Li B, Chen J, Liu D, et al. Haplotypic analyses of the aldosterone synthase gene CYP11B2 associated with stage-2 hypertension in northern Han Chinese. Clin Genet 2004; 66:409-416.
24. Stram DO, Haiman CA, Hirschhorn JN, Altshuler D, Kolonel LN, Henderson BE, Pike MC. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003; 55:27-36.
25. Chapman JM, Cooper JD, Todd JA, Clayton DG. Detecting disease associations due to linkage disequilibrium using haplotype tags: a class of tests and the determinants of statistical power. Hum Hered 2003; 56:18-31.
26. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70:425-434.
27. Lake SL, Lyon H, Tantisira K, Silverman EK, Weiss ST, Laird NM, Schaid DJ. Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous. Hum Hered 2003; 55:56-65.
28. Kang BY, Bae JS, Lee KO. Genetic analysis of kallikrein-kinin system in the Korean hypertensives. Korean J Biol Sci 2004; 8:41-47.
29. Iwai N, Tago N, Yasui N, Kokubo Y, Inamoto N, Tomoike H, Shioji K. Genetic analysis of 22 candidate genes for hypertension in the Japanese population. J Hypertens 2004; 22:1119-1126.
30. Brault AC, Powers AM, Holmes EC, Woelk CH, Weaver SC. Positively charged amino acid substitutions in the e2 envelope glycoprotein are associated with the emergence of venezuelan equine encephalitis virus. J Virol 2002; 76:1718-1730.
31. Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 2001; 22:184-204.
32. Reich DE, Lander ES. On the allelic spectrum of human disease. Trends Genet 2001; 17:502-510.
33. Lander ES. The new genomics: global views of biology. Science 1996; 274:536-539.
34. Gu D, Su S, Ge D, Chen S, Huang J, Li B, et al. Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese. Hypertension 2006; 47:1147-1154.
35. Komar AA. Genetics: SNPs, silent but not invisible. Science 2007; 315:466-467.
36. Cardon LR, Abecasis GR. Using haplotype blocks to map human complex trait loci. Trends Genet 2003; 19:135-140.
37. Zhang K, Qin Z, Chen T, Liu JS, Waterman MS, Sun F. HapBlock: haplotype block partitioning and tag SNP selection software using a set of dynamic programming algorithms. Bioinformatics 2005; 21:131-134.
38. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003; 361:567-571.
39. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005; 366:1315-1323.
40. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001; 2:91-99.